ASTE

Astec Industries

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Industrials

industry

Farm & Heavy Construction Machinery

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/05/26

Business Summary

AnaptysBio is a clinical-stage biotechnology company focused on developing antibody therapeutics for inflammatory and immune-mediated diseases. The business model centers on discovering and advancing proprietary biologic drug candidates, then monetizing them either through commercialization or strategic partnerships. Cash generation typically comes from milestone payments, licensing agreements, and potential product revenues if candidates reach approval. The moat, such as it is, lies in proprietary antibody engineering capabilities and intellectual property, where successful clinical validation can create significant pricing power and long-duration revenue streams protected by patents.

VALUATION

P/E

36.5

Market Cap ($M USD)

$1,403

Forward P/E

14

PEG

1.3

PRICE TO SALES

1

PRICE TO BOOK

2.1

EV / EBITDA

15.5

5-Year Average P/E

DIVIDEND

Yield

0.90%

Annual Payout

$0.52

Payout Ratio

30.60%

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

3.40%

Financial Health & Profitability

Earnings Per Share

$1.70

Next Year EPS Growth Estimate

$4.39

Next Year Revenue Growth Estimate

5.40%

Return on Equity (ROE)

5.70%

Operating Margin

4.60%

Debt-to-Equity

0.5

Piotroski F-Score

5

Altman Z-Score

3.4

Return on Invested Capital (ROIC)

5.60%%

Current Ratio

2.5

Quick Ratio

Gainseekers Quantitative Analysis

Summary

The market is treating ANAB like a binary biotech option rather than a compounding enterprise. There is no Forward P/E and no PEG Forward, which immediately tells you forward visibility is poor and earnings durability is in question, while the Altman Z-Score of 2.8 signals balance sheet stability that is adequate but not bulletproof. The stock trades at 8.6x sales and an extreme 54.1x book value, pricing in asset-light intellectual property rather than hard equity, yet it generates a 56.80% ROIC and 60.70% ROE — numbers that are elite on paper. This is a financially strong but operationally inconsistent business with a stretched valuation multiple relative to its current -35.60% operating margin profile, meaning the market is paying for scientific upside, not present profitability.

AI Exposure / Tech Reliance

As a Biotechnology company in Healthcare, ANAB operates in an industry where AI increasingly accelerates drug discovery, target identification, and clinical trial optimization. That structural shift favors companies with focused pipelines and strong capital efficiency, particularly those already producing high ROIC. However, biotech remains fundamentally driven by clinical outcomes rather than incremental tech adoption, so AI is an enhancer, not a guarantee.

The Bull Case

A disciplined GARP or deep value investor could justify a position based on capital efficiency and financial resilience. A 56.80% ROIC paired with 60.70% ROE is exceptional, especially when combined with a Piotroski F-Score of 6, indicating solid fundamental momentum rather than deterioration. The current ratio of 9.1 provides substantial liquidity, reducing near-term financing risk, while Debt/Equity of 20.40% suggests leverage is present but not excessive for a biotech. Institutional ownership at 80.75% implies serious capital allocators see asymmetric optionality, and with a market cap of $2,015M, the company is large enough to matter yet small enough to re-rate significantly if pipeline execution improves.

The Bear Case

The bear case is equally forceful. Operating margin sits at -35.60%, EPS next year is estimated at -$0.46, and Sales Growth Next Year is projected at -$3.54, signaling a sharp deterioration from the current EPS of 24.8 — a massive earnings swing that raises quality-of-earnings concerns. There is no Forward P/E and no PEG Forward, which underscores the absence of reliable forward profitability metrics. Price/Sales of 8.6 and Price/Book of 54.1 are aggressive for a company with negative forward earnings and shrinking sales expectations, and the Altman Z-Score of 2.8 is not comfortably high for a biotech facing operational losses. Consensus Rating at 30.60% and a Mean Consensus Target Price of 1.29 suggest muted analyst conviction, reinforcing that this is a high-risk, execution-dependent story rather than a stable compounder.

Market Sentiment & Smart Money

Short Interest %

2.60%

Analyst Consensus

1

Average Analyst Price Target

$68.33

Institutional Ownership %

99.60%

1-Year Beta

1.63

Insider Buying % (6 Mo)

1.10%%

Distance to 52-Week High

95.10%%

Distance to 52-Week Low

192.00%%